Aspira Women's Health Provides A Development Update On Its Portfolio Of Noninvasive Tests For Endometriosis
Portfolio Pulse from Benzinga Newsdesk
Aspira Women's Health Inc. (AWH) has completed the design of EndoCheck, a blood test for localized endometriosis, and plans a commercial launch in 2024. The test shows promise as a non-invasive alternative to laparoscopic surgery for diagnosing endometriomas. Aspira is collaborating with The University of Oxford and The Dana Farber Cancer Institute for validation and research. The company is also developing EndoMDx for broader endometriosis indications and is in talks with potential partners to drive shareholder value. An Analyst Day event is scheduled for January 2024.
December 06, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aspira Women's Health has developed EndoCheck, a promising non-invasive test for endometriosis, with a commercial launch planned for 2024. The company is also advancing EndoMDx and engaging in strategic partnership discussions.
The development of EndoCheck positions AWH at the forefront of non-invasive gynecologic diagnostics, potentially disrupting the current standard of care. The commercial launch and ongoing development of EndoMDx, along with strategic partnership talks, are likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100